FDA approves KEYTRUDA (pembrolizumab) as monotherapy for metastatic SLCc
Merck announced the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. June 18, 2019